Ji Li
EVP, Global Head of Business Development
chemical
BeiGene
China
Biography
More than 18 years of Business Development and R&D experience in biopharma industry Former member of the Board of Directors of BeiGene, as a representative for Merck, up until BeiGene’s IPO in February 2016 Former Vice President of Business Development and Licensing at Merck & Co. Inc Former Executive Licensing Director, External R&D at Amgen Key member of Amgen research team discovered and validated the RANKL signaling pathway that has led to the development of Denosumab, the current standard of care therapy for osteoporosis, cancer bone metastasis and other bone loss indications. Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York B.S. in Pharmacology from Shanghai Medical University
Research Interest
biochemistry
